Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

Unlike conventional Coronavirus 2019 (COVID-19) vaccines, intranasal vaccines display a superior advantage because the nasal mucosa is often the initial site of infection. Preclinical and clinical studies concerning intranasal immunization elicit high neutralizing antibody generation and mucosal IgA...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Discov Today
Autors principals: Chavda, Vivek P., Vora, Lalitkumar K., Pandya, Anjali K., Patravale, Vandana B.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Ltd. 2021
Matèries:
Keynote (Green)
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8319039/
https://ncbi.nlm.nih.gov/pubmed/34332100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2021.07.021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars